What BMI do you need for Zepbound under BCBS Minnesota?

For weight loss on Employer / Commercial Insurance plans, BCBS Minnesota requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.

How long does a Zepbound approval last with BCBS Minnesota?

Initial approvals last 12 months, and renewals are granted in 12-month periods.

What does BCBS Minnesota require to renew Zepbound?

At least 5% weight loss from the starting weight and For renewal: patient has achieved and maintained >= 5% weight loss from baseline (prior to initiation of the requested agent), OR patient has received less than 52 weeks of therapy on the maximum-tolerated dose. Pediatric renewal also requires current BMI >= 85th percentile for age and sex. Patient must continue weight management regimen and not combine with another weight loss agent or GLP-1.

What if my plan excludes weight loss medications?

BCBS Minnesota has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.

How current is this information?

This page reflects BCBS Minnesota's written policy as of April 1, 2026, last verified against the source document on June 5, 2026.

BCBS Minnesota

Does BCBS Minnesota cover Zepbound?

Quick answer · Weight Loss

BCBS Minnesota covers it only when the plan's benefit includes it on Employer / Commercial Insurance.

Employer / Commercial Insurance: Depends on your plan's benefit. Weight loss must NOT be excluded from coverage under the patient's pharmacy benefit. Applies to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open for weight loss agents on coverage delay.

Last verified June 5, 2026. Policy effective April 1, 2026. Source: Pa policy. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What BCBS Minnesota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Weight loss must NOT be excluded from coverage under the patient's pharmacy benefit. Applies to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open for weight loss agents on coverage delay.

What you need to qualify

Age 12 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, T2DM, OSA, CVD, and dyslipidemia)
BMI of 25 or higher for patients of Asian descent
BMI at or above the 95th percentile for age and sex
6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult Weight Management

All of:

Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
Patient is an adult (18 years of age or over)
Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
Patient will NOT use the requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Patient is currently on and will continue weight management regimen
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient's age is within FDA labeling OR there is support for use at patient's age
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

BMI >= 30 kg/m2
BMI >= 25 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
BMI >= 27 kg/m2 with at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, T2DM, OSA, CVD, dyslipidemia)

Pediatric Weight Management (12-17 years)

All of:

Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
Patient is pediatric (12 to 17 years of age)
Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
Patient will NOT use the requested agent in combination with another weight loss agent
Patient is currently on and will continue weight management regimen
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient's age is within FDA labeling OR there is support for use at patient's age
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

BMI >= 95th percentile for age and sex
BMI >= 30 kg/m2
BMI >= 85th percentile for age and sex AND at least one severe weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, T2DM, OSA)

Repeat Course of Therapy (prior weight loss agent in past 12 months)

All of:

Patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months
Prescriber anticipates success with repeating therapy with any targeted weight loss agent
All other standard weight management criteria met

Documentation to bring

Documentation of BMI (>= 30 kg/m2, or >= 27 kg/m2 with comorbidity, or >= 25 kg/m2 if South/Southeast/East Asian)
Documentation of 6-month weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
Documentation of weight loss less than 1 pound per week on weight management regimen prior to pharmacotherapy
Documentation that weight loss is not excluded from coverage under the patient's pharmacy benefit
Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful
For pediatric patients: documentation of age (12-17), BMI percentile for age and sex, and qualifying comorbidities if applicable
For repeat course: documentation of prior targeted weight loss agent use and prescriber attestation of anticipated success

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight and For renewal: patient has achieved and maintained >= 5% weight loss from baseline (prior to initiation of the requested agent), OR patient has received less than 52 weeks of therapy on the maximum-tolerated dose. Pediatric renewal also requires current BMI >= 85th percentile for age and sex. Patient must continue weight management regimen and not combine with another weight loss agent or GLP-1. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Co-administration with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Co-administration with another GLP-1 receptor agonist
Any FDA labeled contraindications
Weight loss coverage excluded from pharmacy benefit

Policy note: Policy applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx formularies. Weight loss agents on coverage delay apply to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open. For the 6-month lifestyle program, the patient must not have lost >= 1 lb/week (i.e., inadequate response to lifestyle). For renewal: Zepbound weight loss renewal requires either < 52 weeks of therapy on maximum-tolerated dose OR >= 5% weight loss from baseline. Pediatric renewal additionally requires current BMI >= 85th percentile. Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy

Zepbound for Osa

What BCBS Minnesota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Depends on your plan's benefit

Expanded indications must NOT be restricted from coverage under the patient's pharmacy benefit.

What you need to qualify

Age 18 and older
BMI of 30 or higher
Prescribed by or in consultation with a specialist
Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

OSA with Obesity — Initial Approval

All of:

Diagnosis of obstructive sleep apnea (OSA)
Expanded indications are NOT restricted from coverage under the patient's pharmacy benefit
Patient has had a polysomnography (PSG) or home sleep apnea test
Patient has an apnea hypopnea index (AHI) >= 15 events/hour from baseline (prior to initiation of pharmacotherapy)
Requested agent is Zepbound
Patient has a BMI >= 30 kg/m2
Patient does NOT have craniofacial abnormalities that may affect breathing
Patient does NOT have a diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas >= 50%
Patient does NOT have a diagnosis of Cheyne Stokes Respiration
Patient does NOT have a diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
Prescriber is a specialist (e.g., pulmonologist, sleep specialist) or has consulted with a specialist
Patient will NOT use the requested agent in combination with another weight loss agent
Patient is currently on and will continue weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Documentation to bring

Medical records documenting diagnosis of obstructive sleep apnea (OSA)
Results of polysomnography (PSG) or home sleep apnea test showing AHI >= 15 events/hour from baseline (prior to pharmacotherapy initiation)
Documentation of BMI >= 30 kg/m2
Documentation ruling out: craniofacial abnormalities affecting breathing, Central or Mixed Sleep Apnea with >= 50% central/mixed apneas-hypopneas, Cheyne Stokes Respiration, Obesity Hypoventilation Syndrome or daytime hypercapnia
Documentation of specialist involvement (pulmonologist or sleep specialist) or consultation
Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for At renewal: patient must have had clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). Specialist requirement is re-verified. AHI >= 15 threshold is NOT re-verified at renewal — only clinical benefit is required.

Not covered when

Craniofacial abnormalities that may affect breathing
Diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas >= 50%
Diagnosis of Cheyne Stokes Respiration
Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
Co-administration with another weight loss agent
Co-administration with another GLP-1 receptor agonist
Any FDA labeled contraindications
Expanded indications restricted from coverage under patient's pharmacy benefit

Policy note: PAP therapy trial is NOT required prior to approval — this is an expanded indication. The policy does not require that PAP therapy be tried or failed. OSA indication requires AHI >= 15 events/hour (moderate-to-severe OSA threshold) from baseline prior to pharmacotherapy initiation, confirmed by PSG or home sleep apnea test. Renewal requires clinical benefit (e.g., AHI reduction, Epworth Sleepiness Scale improvement) but does not re-require the baseline AHI >= 15 threshold. Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy

Why Zepbound requests get denied by BCBS Minnesota

Based on what this policy asks for. Fix these before the first submission.

Your specific plan doesn't include the weight loss benefit. Coverage here is conditional on the benefit design (often an optional employer add-on), so confirm it before submitting.
Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
BMI not documented in the chart notes (or documented without a baseline weight and date).
Qualifying weight-related condition not documented with its own diagnosis code.
No documented diet and exercise program.
Prescriber isn't the specialist the plan requires.
Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

BCBS Minnesota has separate Zepbound policies that don't depend on the weight loss benefit:

Osa — covered on Employer / Commercial Insurance.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does BCBS Minnesota cover Zepbound?: BCBS Minnesota covers it only when the plan's benefit includes it on Employer / Commercial Insurance.
What BMI do you need for Zepbound under BCBS Minnesota?: For weight loss on Employer / Commercial Insurance plans, BCBS Minnesota requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition.
How long does a Zepbound approval last with BCBS Minnesota?: Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Minnesota require to renew Zepbound?: At least 5% weight loss from the starting weight and For renewal: patient has achieved and maintained >= 5% weight loss from baseline (prior to initiation of the requested agent), OR patient has received less than 52 weeks of therapy on the maximum-tolerated dose. Pediatric renewal also requires current BMI >= 85th percentile for age and sex. Patient must continue weight management regimen and not combine with another weight loss agent or GLP-1.
What if my plan excludes weight loss medications?: BCBS Minnesota has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?: This page reflects BCBS Minnesota's written policy as of April 1, 2026, last verified against the source document on June 5, 2026.

Other medications under BCBS Minnesota

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Minnesota's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.